

1649




# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 28, 2003

<p>CERTIFICATE OF MAILING 37 C.F.R. 1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:</p> <p>April 28, 2003 Date</p> <p> Gina N. Shishima</p>
---

RECEIVED

MAY 06 2003

TECH CENTER 1600/2900

**Box DD**  
Commissioner for Patents  
Washington, DC 20231

Re: *U.S. Patent Application No. 10/057,834 entitled "COMPOSITIONS AND METHODS FOR OPTIMIZING UGT2B7 SUBSTRATE DOSINGS AND FOR PREDICTING UGT2B7 SUBSTRATE TOXICITY" by Mark J. Ratain et al.*  
*Client Reference: UCIII:846*  
*Our Reference: ARCD:358US*


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C27-C28).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:358US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Gina Shishima  
Reg. No. 45,104

GNS/cas  
Encl.: As noted

252813741



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Mark J. Ratain et al.

Serial No.: 10/057,834

Filed: January 25, 2002


For: COMPOSITIONS AND METHODS FOR  
OPTIMIZING UGT2B7 SUBSTRATE  
DOSINGS AND FOR PREDICTING  
UGT2B7 SUBSTRATE TOXICITY

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: ARCD:358US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

<p>CERTIFICATE OF MAILING 37 C.F.R. 1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:</p> <p>April 28, 2003 Date</p> <p> Gina N. Shishima</p>
---

RECEIVED

MAY 11 6 2003

TECH CENTER 1600/2900

**BOX DD**  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:358US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima  
Reg. No. 45,104  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: April 28, 2003

Form PTO-1449 (modified)

Atty. Docket No.  
ARCD:358USSerial No.  
10/057,834

List of Patents and Publications for Applicant's

Applicant  
Mark J. Ratain *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
January 25, 2002Group:  
1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C27	Lampe et al., "Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)." <i>Cancer Epidemiology, Biomarkers and Prevention, American Association for Cancer Research</i> , 9:329-333, 2000.
	C28	Holthe et al., "Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy." <i>European Journal of Clinical Pharmacology</i> , 58: 353-356, 2002.

RECEIVED

MAY 06 2003

TECH CENTER 1600 2900

25280672.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE IS CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPE-P009. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)